

Dr. Young Kee Shin is interested in developing the promising New Molecular Entity(NME), including antibody, siRNA, small molecule that targets cancer and other diseases. From these candidates, he aims to propose proof-of concept. Death Valley, which must be overcome for the development of new drugs, is a stage in basic science that progresses into clinical research and difficulty in actual clinical application when clinical trials are completed and commercialized. In order to achieve this, we delve deeply in researching biomarkers, regulatory science, exploratory clinical trials. Additionally, approaching from a different perspective, drug economics considering cost-effectiveness is also critical. From these, we can ultimately develop new drugs with corporations. Noteworthy, Dr. Young Kee Shin is a pioneering researcher in the field of companion diagnosis. Being the head of companion diagnosis enterprise organization, he developed kits that can detect genetic mutations in breast cancer, lung cancer and colon cancer. He also transferred patents and technologies to the industry's leading companies. In addition, he participated two of the initial tasks including authorization and screening of Food and Drug Administration's the 'In Vitro Companion Diagnostic Devices.' From this, he developed technologies and policies in the field of companion diagnosis which upgraded the techniques of the field.